Trials / Completed
CompletedNCT03278262
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
INSIGHT - The Impact of baseliNe viSual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical settinG. Analysis of Data From the SwedisH Macula RegisTer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,312 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting. In addition, the study will ascertain the baseline VA in treatment -naïve Wet Age-Related Macular Degeneration or neo-vascular AMD (wAMD) patients who start treatment with Aflibercept in a real-life setting and it will assess the impact of baseline VA on the outcomes of Aflibercept treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, BAY86-5321) | Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient. |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2017-09-11
- Last updated
- 2018-10-29
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03278262. Inclusion in this directory is not an endorsement.